Anastrozole on TRT
Anastrozole is the aromatase inhibitor most commonly used in the TRT community — and unlike exemestane, it has several real RCTs conducted directly in older and hypogonadal men. The picture from those trials is genuinely mixed: hormones respond predictably, but symptoms don't always follow, and one trial found a real, statistically significant drop in bone density.
Number of studies
7
Safety
Requires caution
Time to effects
Changes in blood estradiol and testosterone are usually visible within a few weeks (in the cited Leder et al. RCT, hormonal effects were already assessed after a short treatment period). Improvement in subjective symptoms, if it occurs at all, is far less predictable and did not differ significantly from placebo in two independent RCTs.
Monthly cost
ok. 10–40 zł/miesiąc przy typowych, niskich dawkach off-label
Price in Poland
ok. 20–50 zł za opakowanie, zależnie od dawki i liczby tabletek
Who it's for
Anastrozol jest zwykle tańszy niż eksemestan, co częściowo tłumaczy jego powszechniejsze stosowanie off-label, niezależnie od kwestii dowodowych.
Indicative prices for the Polish market — we don't point to specific retailers; the real price depends on the manufacturer, form and place of purchase.
Table of contents
TL;DR
Anastrozole is the aromatase inhibitor most commonly used in the TRT community — and unlike exemestane, it has several real RCTs conducted directly in older and hypogonadal men. The picture from those trials is genuinely mixed: hormones respond predictably, but symptoms don't always follow, and one trial found a real, statistically significant drop in bone density.
- →A predictable reduction in estradiol and increase in testosterone, documented across several independent RCTs in older and hypogonadal men
- →In one RCT (Herzog et al., 2010, in men with epilepsy and hypogonadism) — significant improvement in sexual function versus testosterone alone
- →A reversible mechanism of action — aromatase activity returns relatively quickly after discontinuation, without needing to rebuild the enzyme pool
| Active substance | Anastrozole |
|---|---|
| Drug class | Non-steroidal, reversible aromatase inhibitor (type II) |
| Approved use | Hormone-receptor-positive breast cancer in postmenopausal women — TRT use is off-label |
| Evidence in men | Several RCTs in older/hypogonadal men — the best-documented AI in this context |
| Evidence level | Moderate — real RCT data, but inconsistent clinical results and a documented bone risk |
| Status | Prescription drug; TRT use is off-label only, under physician supervision |
Understand
Overview
Anastrozole is a non-steroidal, reversible third-generation aromatase inhibitor, originally approved for treating hormone-receptor-positive breast cancer in postmenopausal women. In the TRT (testosterone replacement therapy) community, it is by far the most commonly used off-label aromatase inhibitor — used by some physicians and patients to control the elevated estradiol that naturally results from aromatizing externally administered testosterone. Unlike exemestane, whose use in men rests essentially on extrapolation from oncology and a single small trial in adolescents, anastrozole has several genuine, placebo-controlled randomized trials conducted directly in older and hypogonadal men. That makes it by far the best-documented aromatase inhibitor used in the context of male hormone therapy — but, just as importantly, that documentation doesn't paint an unambiguously positive picture.
The picture emerging from these trials is genuinely mixed, and this entry aims to present it honestly rather than resolving the controversy one way or the other. First, hormones respond to anastrozole exactly as the mechanism predicts — testosterone rises, estradiol falls, reproducibly and statistically significantly across multiple independent trials. Second, and this is the much less convenient part of the picture, improved hormonal markers on paper doesn't necessarily translate into improved symptoms. Two independent RCTs (Leder et al. 2004, Burnett-Bowie et al. 2009) found significant improvement in hormonal profile alongside no significant improvement in sexual function or body composition relative to placebo — exactly the scenario skeptics of routine aromatase-inhibitor use warn about: 'better' bloodwork on paper, without a noticeable difference for the patient.
On the other side of this picture stands a study by Herzog and colleagues (2010), which found a real, statistically significant improvement in sexual function when anastrozole was added to testosterone in hypogonadal men — directly contradicting the null results of the two studies above. An honest treatment of this topic requires acknowledging: we have real, conflicting RCT results, not a clear consensus. An important methodological detail is worth noting here — the Herzog study was conducted in a specific population of men with epilepsy and hypogonadism, an additional factor that differentiates this group from a typical, general TRT patient and complicates simple generalization of the result.
The most serious, and arguably the single most important piece of this whole evidence picture, is the finding from Burnett-Bowie and colleagues' 2009 study, dedicated specifically to evaluating anastrozole's effect on bone mineral density in older men with low testosterone. The result was unambiguous and concerning: spine bone density in men on anastrozole genuinely decreased over the course of the trial, while the placebo group's spine density increased over the same period — a statistically significant difference (P=0.0014). This isn't a theoretical, extrapolated risk — it's a direct, measured adverse effect demonstrated in a controlled clinical trial in humans, and it should weigh heavily in any decision about long-term, routine use of this drug.
This evidentiary ambiguity is reflected in the medical community's positions. A review by de Ronde and de Jong (2011), focused specifically on aromatase-inhibitor use in men, concludes outright that the long-term efficacy and safety of this drug class in men has not yet been established, and that routine use is not yet recommended. The European Academy of Andrology (EAA), in its clinical guidelines on gynecomastia, explicitly advises against using aromatase inhibitors (alongside SERMs and non-aromatizable androgens) to treat gynecomastia — which, while addressing a different, narrower clinical context than general estradiol management on TRT, reflects the same broader expert skepticism about routine use of this drug class in men. Mainstream endocrinology guidelines on testosterone therapy do not include routine aromatase-inhibitor use as a standard part of a TRT protocol.
What does all this mean in practice? Anastrozole is not a drug whose use on TRT is unambiguously 'proven' or unambiguously 'debunked' — it's a drug with a real, confirmed hormonal effect, an inconsistent clinical effect, and a documented, serious potential risk to bone health with longer use. The decision to add it to a TRT protocol should be an individual clinical decision, made together with a physician experienced in managing testosterone therapy, based on specific, repeated bloodwork and the patient's actual symptoms — not on the assumption that 'everyone on TRT should be taking something for estrogen', and not on a desire to drive estradiol as low as possible.
Mechanism of action
Anastrozole is a non-steroidal type II aromatase inhibitor — it works reversibly and competitively, binding the heme prosthetic group of the aromatase enzyme without permanently, covalently binding it, unlike steroidal 'suicide' type I inhibitors such as exemestane. This reversibility means aromatase activity returns relatively quickly after stopping the drug or as its blood concentration falls, without the body needing to synthesize entirely new enzyme molecules.
By blocking aromatase, anastrozole limits the conversion of testosterone and androstenedione into estradiol and estrone in peripheral tissues, mainly fat tissue. This effect is well documented quantitatively in RCTs in older men: in Leder and colleagues' trial (2004), bioavailable testosterone rose from 99±31 to 207±65 ng/dL, and estradiol fell from 26±8 to 17±6 pg/mL. In an independent trial by Burnett-Bowie and colleagues (2009), testosterone rose from 11.2±3.3 to 18.2±4.8 nmol/L by month three, and estradiol fell from 55.8±15.4 to 42.2±13.6 pmol/L. These two independent trials confirm that anastrozole's hormonal effect is real, reproducible, and predictable — that isn't the contested part.
What is contested, and clinically far more important, is what this hormonal change means for the patient's well-being and health. Key mechanistic insight into why a change in blood numbers doesn't necessarily translate into symptom improvement comes from a study by Finkelstein and colleagues (2013, New England Journal of Medicine) — an experiment specifically designed to separate the independent effects of androgens and estrogens in men, by pharmacologically shutting down endogenous sex-hormone production (goserelin) and administering graded testosterone doses, with or without anastrozole. The results showed a clear division of roles: declining sexual desire depended on androgen (testosterone) dose, while increased body fat depended specifically on estrogen deficiency. Both hormones therefore play distinct, partially non-overlapping roles — meaning that lowering estradiol with an aromatase inhibitor isn't simply 'amplifying' testosterone's effect, but a separate intervention with its own, partly distinct benefit-risk profile.
The mechanism underlying the most serious documented risk — bone density loss — has also been explained at the physiological level. A later study by the same team (Finkelstein et al., 2016, Journal of Clinical Investigation) found that when aromatization was pharmacologically blocked, spine bone mineral density, measured by both DXA and quantitative CT (QCT), fell significantly across all tested testosterone-dose groups — confirming that estrogen, not testosterone, is the primary hormonal regulator of bone density maintenance in men. This is precisely the mechanism that physiologically explains why the Burnett-Bowie et al. (2009) finding — a real drop in spine bone density on anastrozole while the placebo group's density rose — is not a random, isolated result, but a consistent, predictable effect of blocking aromatization in men.
Reversible binding to aromatase
Anastrozole competitively and reversibly binds the heme in aromatase's active site, blocking its ability to convert androgens into estrogens, without permanently deactivating the enzyme.
Reduced conversion to estradiol
The blocked aromatase no longer converts testosterone and androstenedione into estradiol and estrone in fat tissue and other peripheral tissues.
Testosterone rises, estradiol falls
An effect confirmed in multiple independent RCTs: testosterone rises and estradiol falls, reproducibly and statistically significantly.
Distinct effects on androgen- and estrogen-dependent tissues
Trials separating testosterone and estrogen effects show sexual desire depends mainly on androgen, while body composition and bone density depend heavily on estrogen.
Potential effect on bone density
Lowering estradiol below the level the body needs may slow or reverse gains in spine bone mineral density, as shown in a dedicated RCT.
Evidence: moderate — based on 7 studies in this database.
Benefits
Common myths
MythSince anastrozole raises testosterone and lowers estradiol, it automatically improves well-being and sexual function.
FactTwo independent RCTs (Leder et al. 2004, Burnett-Bowie et al. 2009) found significant improvement in hormonal markers alongside no significant improvement in sexual function or body composition versus placebo. A third trial (Herzog et al. 2010, in a specific population of men with epilepsy) found improvement — the evidence is genuinely conflicting, not unambiguously positive.
MythAnastrozole is safe for long-term, routine use on TRT because it's well studied.
FactA dedicated RCT found a statistically significant drop in spine bone mineral density in men on anastrozole, while the placebo group's bone density rose over the same period. One of the best-documented studies on this drug actually demonstrates real risk, not safety.
MythMajor endocrinology societies recommend adding an aromatase inhibitor to every TRT protocol.
FactThe opposite is true — a review by de Ronde and de Jong (2011) concludes that the long-term safety and efficacy of aromatase inhibitors in men has not been established, and that routine use is not recommended. European Academy of Andrology guidelines on gynecomastia explicitly advise against their use in that context.
Forms & variants
Anastrozole on TRT comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Anastrozole — generic formulation
The most commonly prescribed, generic form of the drug, available by prescription; the active substance is identical to the original product studied in the cited RCTs.
Best for: The standard choice when a physician decides to add an aromatase inhibitor to a TRT protocol
Anastrozole combined with a lower testosterone dose
Some physicians prefer lowering the testosterone dose (which proportionally lowers estradiol too) rather than adding a separate aromatase-blocking drug.
Best for: Patients whose issue is too high a testosterone dose rather than excessive aromatization at an otherwise appropriate dose
Practice
Frequently asked questions
The evidence here is genuinely conflicting. Two independent RCTs (Leder et al. 2004, Burnett-Bowie et al. 2009) found significant improvement in hormonal profile with no significant improvement in sexual function or body composition versus placebo. A third trial (Herzog et al. 2010), conducted in a specific population of men with epilepsy and hypogonadism, found a real improvement in sexual function. There's no clear-cut answer — the clinical effect is inconsistent across trials.
There's no clear, reassuring answer here — a dedicated RCT (Burnett-Bowie et al. 2009) found a statistically significant drop in spine bone mineral density in men on anastrozole, while the placebo group's bone density rose over the same period. Another study (Finkelstein et al. 2016) mechanistically explains this, showing that estrogen, not testosterone, is the primary hormonal regulator of bone density in men. This is a real, documented risk that needs monitoring, not dismissing.
No. Mainstream endocrinology guidelines on testosterone therapy do not include routine aromatase-inhibitor use as a standard part of a TRT protocol, and a review focused specifically on this drug class in men (de Ronde and de Jong, 2011) states outright that routine use is not yet recommended given unestablished long-term safety.
Partly because the trials differed in population (older men with borderline-low testosterone vs. men with epilepsy and hypogonadism), duration, and exact endpoints. That's a normal situation early in research on an off-label drug use — it doesn't mean one trial is 'wrong', just that the clinical effect likely depends on factors not yet fully identified.
Anastrozole works reversibly and competitively, while exemestane irreversibly deactivates the enzyme. The key evidentiary difference: anastrozole has several real RCTs conducted directly in older and hypogonadal men, while the only available data on exemestane in men comes from a small pharmacokinetic study in adolescents and young adults. No study directly compares the two drugs in men.
Yes, definitely — both to confirm the dose is actually correcting estradiol excess without over-suppressing it, and because of the documented bone-density risk with longer use, which warrants periodically considering a densitometry scan during extended therapy.
Dosage & timing
Typical dose
The cited RCTs in older men typically used low doses, ranging from a fraction of a milligram up to 1 mg, several times a week or daily depending on the trial protocol. There is no single, universally validated regimen for every man on TRT — the dose should be set individually by a physician based on baseline and follow-up estradiol levels.
Form
Oral tablets
Dosing is informational and reflects the ranges used in the cited studies — it does not replace consulting a doctor. Given the documented bone-density risk, dosing 'by feel' or based purely on schedules found online is especially irresponsible with this drug.
Best times to take it
- Dosing is individually set by a physician, often lower and less frequent than the doses used in oncology in women might intuitively suggest
- Dose changes should be based on repeated estradiol testing, not day-to-day well-being — the symptoms of estradiol excess and deficiency can be surprisingly similar
- With longer use (months), it's worth discussing periodic bone mineral density monitoring with a physician, given the documented risk shown in RCTs
What to combine with
Use caution with
Exemestane (Symex) on TRT — Both drugs act on the same enzyme via the same general pathway — combining two aromatase inhibitors without a clear medical indication increases the risk of excessive estradiol suppression
Safety
Side effects & contraindications
Possible side effects
A statistically significant drop in spine bone mineral density, documented in a dedicated RCT in older men — the most serious confirmed risk of this drug
In two independent RCTs (Leder 2004, Burnett-Bowie 2009) — no significant improvement in sexual function or body composition despite significant hormonal improvement
Risk of excessive estradiol suppression at too high a dose or too frequent dosing — joint pain, reduced libido, worsened mood, sleep disturbances
Potential unfavorable changes in lipid profile with prolonged, substantial estradiol reduction
Headaches, hot flashes, nausea — reported in oncology populations, less systematically studied in men on TRT
No long-term safety data with many years of continuous use in the TRT population — most cited RCTs lasted weeks to a few months, not years
Contraindications
No confirmed, repeated laboratory-documented elevation in estradiol — routine, prophylactic use is not recommended by mainstream endocrinology guidelines
Osteopenia, osteoporosis, or other documented fracture-risk factors — the documented risk of further bone density loss warrants particular caution or avoiding the drug
Treating gynecomastia as the sole indication — the European Academy of Andrology explicitly advises against aromatase inhibitors in this specific context
Partner planning pregnancy, without prior consultation about effects on the hormonal axis
Use without regular monitoring of estradiol, lipid panel, and, with longer use, bone mineral density
Interactions
Exogenous testosterone as part of TRT — an intentional interaction (controlling aromatization), requiring regular dose adjustment to current bloodwork, not a fixed, rigid schedule
Exemestane and other aromatase inhibitors — no medical justification for combining two drugs with the same mechanism of action without a clear physician indication
Drugs and supplements that reduce bone density (e.g. chronic glucocorticoids) — combining increases the overall risk of bone loss
Tamoxifen and other SERMs — may have pharmacokinetic interactions; the decision to combine belongs to a physician
Is it worth taking?
Who it's for
- Men on TRT with laboratory-confirmed, repeated, symptomatic estradiol excess, under the care of a physician experienced in managing TRT
- Patients for whom lowering the testosterone dose isn't sufficient or desirable, and estradiol-excess symptoms persist despite that
- Not a drug for self-directed, prophylactic use by every man starting TRT — especially given the documented bone-density risk
Not for
- No confirmed, repeated laboratory-documented elevation in estradiol — routine, prophylactic use is not recommended by mainstream endocrinology guidelines
- Osteopenia, osteoporosis, or other documented fracture-risk factors — the documented risk of further bone density loss warrants particular caution or avoiding the drug
- Treating gynecomastia as the sole indication — the European Academy of Andrology explicitly advises against aromatase inhibitors in this specific context
- Partner planning pregnancy, without prior consultation about effects on the hormonal axis
- Use without regular monitoring of estradiol, lipid panel, and, with longer use, bone mineral density
Evidence
Worth knowing
Anastrozole is the most commonly used off-label aromatase inhibitor in the TRT community and has several real RCTs in older/hypogonadal men behind it.
Two independent RCTs found improved hormones without significant improvement in sexual function or body composition versus placebo.
A third RCT (in men with epilepsy) found improved sexual function — the trial results genuinely conflict with each other.
A dedicated RCT found a statistically significant drop in spine bone mineral density on anastrozole, while the placebo group's bone density rose over the same period.
Studies
Spine bone mineral density fell from 1.121±0.141 to 1.102±0.138 g/cm² in the anastrozole group, while the placebo group's density rose from 1.180±0.145 to 1.189±0.146 g/cm² over the same period (P=0.0014).
Burnett-Bowie SA et al., Journal of Clinical Endocrinology & Metabolism, 2009
Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels
Moderate evidenceLeder BZ, Rohrer JL, Rubin SD, et al. · Journal of Clinical Endocrinology & Metabolism · 2004
An RCT in elderly men: bioavailable testosterone rose from 99±31 to 207±65 ng/dL on anastrozole, estradiol fell from 26±8 to 17±6 pg/mL. Despite this clear, significant hormonal improvement, sexual function scores showed no significant change — a real, documented example of a gap between improved bloodwork and improved well-being.
View studyEffects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial
Moderate evidenceBurnett-Bowie SA, Roupenian KC, Dere ME, et al. · Clinical Endocrinology · 2009
A double-blind RCT: testosterone rose from 11.2±3.3 to 18.2±4.8 nmol/L by month three, estradiol fell from 55.8±15.4 to 42.2±13.6 pmol/L. Body composition and sexual outcomes showed no significant change versus placebo — a second independent RCT confirming the same 'hormones improve, symptoms don't' pattern.
View studyEffects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels
Moderate evidenceBurnett-Bowie SA, McKay EA, Lee H, Leder BZ · Journal of Clinical Endocrinology & Metabolism · 2009
An RCT dedicated to evaluating anastrozole's effect on bone: spine bone mineral density fell from 1.121±0.141 to 1.102±0.138 g/cm² in the anastrozole group, while the placebo group's density rose from 1.180±0.145 to 1.189±0.146 g/cm² over the same period (P=0.0014) — direct, statistically significant evidence of real bone-density-loss risk.
View studyGonadal steroid-dependent effects on bone turnover and bone mineral density in men
Strong evidenceFinkelstein JS, Lee H, Leder BZ, et al. · Journal of Clinical Investigation · 2016
When aromatization was pharmacologically blocked, spine bone mineral density, measured by both DXA and QCT, fell significantly across all tested testosterone-dose groups — confirms that estrogen, not testosterone, is the primary hormonal driver of bone density maintenance in men, mechanistically explaining the Burnett-Bowie et al. 2009 finding.
View studyA comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism
Moderate evidenceHerzog AG, Farina EL, Drislane FW, et al. · Epilepsy & Behavior · 2010
Sexual function normalized in 72.2% of the anastrozole+testosterone group versus 47.4% on testosterone alone; sexual-function scores correlated inversely with estradiol levels. A positive finding for anastrozole, directly contradicting the null results of the two studies above — conducted in a specific population of men with epilepsy, an additional limitation on generalizability.
View studyEAA clinical practice guidelines on gynaecomastia evaluation and management
Moderate evidenceKanakis GA, Nordkap L, Bang AK, et al. · Andrology · 2019
European Academy of Andrology clinical guidelines explicitly advise against using SERMs, aromatase inhibitors, and non-aromatizable androgens to treat gynecomastia in men (recommendation R14). Specific to the gynecomastia context, not general estradiol management on TRT, but reflects the same broader expert skepticism about routine use of this drug class in men.
View studyAromatase inhibitors in men: effects and therapeutic options
Moderate evidencede Ronde W, de Jong FH · Reproductive Biology and Endocrinology · 2011
A review concluding that the long-term efficacy and safety of aromatase inhibitors in men has not yet been established, and that their routine use is not yet recommended — a direct, citable statement of the ongoing controversy from a review focused specifically on this drug class in men.
View studySources & bibliography
- PubMed — Leder et al. 2004
- PubMed — Burnett-Bowie et al. 2009 (function/composition)
- PubMed — Burnett-Bowie et al. 2009 (bone density)
- PubMed — de Ronde and de Jong 2011
- PubMed — EAA gynecomastia guidelines 2019
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.3Exemestane (Symex) on TRT
Symex is the Polish brand name for exemestane — a steroidal, irreversible aromatase inhibitor some men on TRT use off-label to control estradiol. The problem: the evidence specifically for exemestane in men is surprisingly thin, and the risk of over-suppressing estrogen is real and documented.
4.6TRT and Estradiol — Why Does Estrogen Rise During Testosterone Therapy?
Many men on TRT watch their estradiol climb on their blood work with alarm. We explain the mechanism of aromatization, which symptoms are genuinely caused by excess estrogen and which are wrongly blamed on it — and why routinely blocking aromatase with an inhibitor is often a mistake.
4.5Estradiol During TRT — What's the Normal Range, and Do You Need to Lower It?
The concrete reference ranges for estradiol in men on TRT, why the standard immunoassay tends to be unreliable in exactly this low concentration range, and how to sensibly interpret a single result — instead of treating it as a verdict demanding immediate action.
4.7TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
Related articles
PoradnikiTRT and Gynecomastia — Why Does Breast Tissue Grow During Testosterone Therapy?
Gynecomastia on TRT is more than a single sentence in an article about side effects — it's a specific hormonal mechanism you can recognize yourself, track over time, and genuinely treat. A deep guide to aromatization, self-exams, and the real treatment options, from watchful waiting to surgery.
August 15, 2026
PoradnikiTRT and High Estradiol — Symptoms, Causes, and What You Can Do About It
Suspect you have high estradiol on TRT? Before you reach for a forum post and someone else's anastrozole protocol, check which symptoms actually point to it and what order to act in — from bloodwork, through talking to your doctor, to a possible medication.
August 15, 2026
PoradnikiTRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy
Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.
July 29, 2026
PoradnikiLow Testosterone: 12 Symptoms Men Often Don't Connect to Their Hormones
Fatigue, a flatter mood, trouble building fitness despite training — most men blame these on age, stress, or a lack of willpower. We look at which symptoms are actually worth linking to low testosterone, and why none of them, on its own, proves anything.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.